Cingal 4ml

Cingal 4 ml combines a high-concentration, cross-linked sodium hyaluronate with a long-acting corticosteroid. The formulation contains 22.0 mg/ml hyaluronic acid and 4.5 mg/ml triamcinolone hexacetonide, providing 88 mg HA and 18 mg steroid per syringe.

The cross-linked HA restores joint lubrication and shock absorption, prolonging residence time and mechanical support. The steroid component offers immediate anti-inflammatory and analgesic relief. Together, they deliver rapid pain reduction followed by durable functional improvement — all in a single injection.

Cingal 4 ml is indicated for symptomatic treatment of osteoarthritis pain, most commonly in the knee, but applicable to other synovial joints per the IFU and local regulatory approvals. It is designed for patients in whom conservative therapies and simple analgesics are inadequate.

Cingal 4 ml is supplied as 1 × 4.0 ml prefilled syringe in a terminally sterilized glass container. Each unit includes the IFU and traceability labels for patient documentation.

Cingal provides fast pain relief within days from the steroid component and sustained improvement lasting up to ~26 weeks (≈6 months) from the HA matrix. Clinical trials demonstrated significant pain and function improvement compared with saline up to 26 weeks, with some patients maintaining benefits beyond this period.

Q1: What does Cingal contain?
Cingal combines 22 mg/ml cross-linked sodium hyaluronate and 4.5 mg/ml triamcinolone hexacetonide (88 mg HA + 18 mg steroid per 4 ml).

Q2: Is Cingal CE-marked or FDA-approved?
Cingal is CE-marked and approved in multiple international markets. It is not approved for use in the United States. Always confirm your country’s regulatory status and keep CE or IFU documentation on file.

Q3: How long do effects last?
Rapid relief typically begins within days; durable improvement is reported for up to 26 weeks (~6 months).

Q4: Can it be used alongside other injections?
Do not mix Cingal with other injectables in the same syringe. Follow spacing intervals and IFU guidance before any additional intra-articular procedures.

Manufacturer: Anika Therapeutics, Inc. — a global leader in joint preservation and regenerative solutions.
Cingal is described by Anika as the first single-injection therapy combining cross-linked HA with triamcinolone hexacetonide for immediate and sustained osteoarthritis pain relief.